KROS FY 2023 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$151,000

Gross Profit

$151,000100.0% margin

Operating Income

-$170M-112543.7% margin

Net Income

-$153M-101319.2% margin

EPS (Diluted)

$-5.20

Cash Flow

Operating Cash Flow

-$125M

Free Cash Flow

-$127M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$370M

Total Liabilities

$38M

Stockholders' Equity

$332M

Cash & Equivalents

$331M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$151,000	$0	—
Gross Profit	$151,000	$0	—
Operating Income	-$170M	-$115M	-48.0%
Net Income	-$153M	-$105M	-46.2%